Wednesday, June 10, 2026

Patent intelligence · US

US 7918899

Variably crosslinked tissue

granted A61KA61K35/32A61K35/36A61K38/39
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 5
Applicant portfolio 201
Patent details — US 7918899
Jurisdiction
US
Status
granted
Grant date
Apr 5, 2011
Expiration
Mar 31, 2031
Claims
31
CPC classes
A61K, A61K35/32, A61K35/36, A61K38/39
View on Google Patents ↗

Quick answer

US 7918899 (Variably crosslinked tissue) is held by Biomedical Design, Inc.. Status: granted. Granted Apr 5, 2011. Expires Mar 31, 2031 (5 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
31
CPC classes
A61K, A61K35/32, A61K35/36, A61K38/39

More from Biomedical Design, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12378245

    Crystalline forms of an RSK inhibitor

    PHOENIX MOLECULAR DESIGNS · Expires Jul 31, 2045

    granted
  2. US 12297243

    Methods and compositions for reducing the immunogenicity of chimeric notch receptors

    Cell Design Labs, Inc. · Expires May 8, 2045

    granted
  3. US 12291058

    Dispersions for additive manufacturing comprising discrete carbon nanotubes

    MOLECULAR REBAR DESIGN, LLC · Expires May 1, 2045

    granted
  4. US 12268695

    Betulin-containing birch bark extracts and their formulation

    Amryt Pharmaceuticals Designated Activity Company · Expires Apr 3, 2045

    granted
  5. US 12247004

    2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use

    Oxford Drug Design Limited · Expires Mar 6, 2045

    granted
  6. US 12065498

    Methods of making bispecific anti-CD307E and anti-BCMA chimeric antigen receptors and uses of the same

    Cell Design Labs, Inc. · Expires Aug 15, 2044

    granted
  7. US 12005194

    Configurable oxygen concentrator and related method

    SEPARATION DESIGN GROUP LLC · Expires Jun 6, 2044

    granted
  8. US 11998571

    Pharmaceutical composition comprising stem cell-conditioned medium and exosome isolated therefrom as active ingredient for prevention or treatment of ocular disease

    DESIGNED CELLS CO., LTD. · Expires May 30, 2044

    granted

Frequently asked questions

What is US patent 7918899?

US 7918899 (Variably crosslinked tissue) is held by Biomedical Design, Inc.. Status: granted. Granted Apr 5, 2011. Expires Mar 31, 2031 (5 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 7918899?

Biomedical Design, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 201 pharmaceutical patents for this assignee.

When does US 7918899 expire?

Our index shows an expiration date of Mar 31, 2031 (5 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.